Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

NV5 Secures $8M In Federal, State Geospatial Projects

NV5 Global Inc (NASDAQ:NVEE) has secured $8 million in recent contracts to provide geospatial data acquisition and data analytics services to support infrastructure, utility, and natural resource assets for public sector clients. NV5 was awarded two contracts totaling more than $4 million to support the U.S. Geological Survey's 3D Elevation Program in Kentucky…

Benzinga

Guardforce AI Acquires Eight Companies In China For $30M

Guardforce AI Co Ltd (NASDAQ:GFAI) (NASDAQ:GFAIW) entered into two definitive agreements to acquire eight companies in China for $30 million. The deal will be paid in a combination of cash (10%) and restricted ordinary shares of GFAI (90%) at an agreed price of $2/share. As per the first agreement, GFAI will acquire Beijing…

Benzinga

Why Merger Talks Between Electronic Arts And NBCUniversal Failed: Who's A Potential Buyer?

Electronic Arts Inc. (NYSE: EA) shares traded higher by 1.5% on a down day in the market on Tuesday following unconfirmed media reports that EA has been aggressively pursuing a sale of the company.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

What 15 Analyst Ratings Have To Say About Marqeta

Within the last quarter, Marqeta (NASDAQ:MQ) has observed the following analyst ratings:

Benzinga

Expert Ratings for Rhythm Pharmaceuticals

Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter:

Benzinga

MoffettNathanson Maintains Buy Rating for Coinbase Global: Here's What You Need To Know

MoffettNathanson has decided to maintain its Buy rating of Coinbase Global (NASDAQ:COIN) and lower its price target from $600.00 to $200.00. Shares of Coinbase Global are trading down 7.13% over the last 24 hours, at $61.39 per share.

Benzinga

Preview: Allied Esports's Earnings

Allied Esports (NASDAQ:AESE) is set to give its latest quarterly earnings report on Wednesday, 2022-05-25. Here's what investors need to know before the announcement. Analysts estimate that Allied Esports will report an earnings per share (EPS) of $-0.08.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Mid-Day Market Update: Dow Drops Over 200 Points; CynergisTek Shares Jump

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday.

Benzinga

Deutsche Bank Maintains Hold Rating for Zoom Video Comms: Here's What You Need To Know

Deutsche Bank has decided to maintain its Hold rating of Zoom Video Comms (NASDAQ:ZM) and lower its price target from $155.00 to $105.00. Shares of Zoom Video Comms are trading up 5.68% over the last 24 hours, at $94.40 per share.

Benzinga

Benchmark Maintains Buy Rating for Zoom Video Comms: Here's What You Need To Know

Benchmark has decided to maintain its Buy rating of Zoom Video Comms (NASDAQ:ZM) and raise its price target from $124.00 to $128.00. Shares of Zoom Video Comms are trading up 5.68% over the last 24 hours, at $94.40 per share.

Benzinga

Looking Into Zoom Video Comms's Recent Short Interest

Zoom Video Comms's (NASDAQ:ZM) short percent of float has fallen 10.27% since its last report. The company recently reported that it has 9.81 million shares sold short, which is 4.72% of all regular shares that are available for trading.

Benzinga

50 Stocks Moving In Tuesday's Mid-Day Session

Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7 million.

Benzinga

Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know

Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3% over the last 24 hours, at $43.40 per share.

Benzinga

Preview: Change Healthcare's Earnings

Change Healthcare (NASDAQ:CHNG) is set to give its latest quarterly earnings report on Wednesday, 2022-05-25. Here's what investors need to know before the announcement. Analysts estimate that Change Healthcare will report an earnings per share (EPS) of $0.41.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

4 Analysts Have This to Say About Iovance Biotherapeutics

Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings:

Benzinga

Looking Into Marathon Digital Holdings's Recent Short Interest

Marathon Digital Holdings's (NASDAQ:MARA) short percent of float has risen 9.83% since its last report. The company recently reported that it has 18.77 million shares sold short, which is 20.12% of all regular shares that are available for trading.

Benzinga

Apple Watch With Pride Bands Could Hit Stores This Week

Apple Inc (NASDAQ: AAPL) could release pride editions of Watch bands soon, according to Mark Gurman. What Happened: The tech-focused journalist said on Twitter that the new pride version of the Apple Watch is due for an imminent launch.

Benzinga

As Apple Continues In This Trend, Here's How To Play It Bull And Bear

Apple Inc (NASDAQ: AAPL) opened lower on Tuesday after spiking up 3.86% on Monday in a relief bounce that led the S&P 500 to 1.39% higher.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

$100 Invested In Palo Alto Networks 5 Years Ago Would Be Worth This Much

Palo Alto Networks (NASDAQ:PANW) has outperformed the market over the past 5 years by 22.56% on an annualized basis producing an average annual return of 32.51%. Currently, Palo Alto Networks has a market capitalization of $47.62 billion.

Benzinga

Analyst Ratings for Karuna Therapeutics

Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:

Benzinga

8 Analysts Have This to Say About Sage Therapeutics

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

Benzinga

Expert Ratings for United Therapeutics

Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:

Benzinga

Ricky Gervais' Netflix Special Generates Controversy Over Trans Jokes

For the second time within a year, Netflix Inc (NASDAQ: NFLX) has generated controversy with a comedy special poking fun at the transgender community — and this time, the center of agitation is British funnyman Ricky Gervais.

Benzinga

What 7 Analyst Ratings Have To Say About Dollar Tree

Analysts have provided the following ratings for Dollar Tree (NASDAQ:DLTR) within the last quarter:

Benzinga

BCLI: Anticipating News on How NurOwn® Will be Advanced Forward…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT

1 … 422 423 424 425

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.